{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.0","upperLimit":"48.0","value":"25.0"},{"groupId":"OG001","lowerLimit":"24.0","upperLimit":"49.0","value":"48.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"description":"Kaplan-Meier estimates of the time to at least a 50% reduction in self-assessed pain intensity in the joint most affected at Baseline and the confidence intervals were determined along with 95% confidence interval. Patients scored their pain intensity on a 0-100 mm VAS, ranging from no pain (0) to unbearable pain (100). Scores on the 100 mm linear scale were measured to the nearest millimeter from the left. Pain was scored at Baseline; at 6 and 12 hours post-dose; and at 1, 2, 3, 4, 5, 6, and 7 days post-dose.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Participants received 1 intramuscular injection of triamcinolone acetonide 40 mg and 1 sc injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug. Last Observation Carried Forward (LOCF) method was used to impute post dose measurement.","reportingStatus":"POSTED","timeFrame":"Baseline to 7 days post-dose (randomization)","title":"Time to at Least a 50% Reduction in Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (VAS)","type":"SECONDARY","unitOfMeasure":"hours"}